Every 8-K that Zevra Therapeutics Inc (ZVRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ZVRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZVRA filings page.
Zevra Therapeutics reported Q2 2026 net revenue of $39.7 million, a 53% increase over Q2 2025. Revenue included $30.2 million from MIPLYFFA, $0.2 million from OLPRUVA, $9.0 million in reimbursements from the global Expanded Access Program, and $0.3 million from AZSTARYS royalties and other reimbursements.
Cost of product revenue was $1.5 million, and operating expenses were $21.0 million, including $3.0 million of stock compensation. Net income was $8.8 million, or $0.14 per basic and diluted share. Excluding warrant and CVR fair value adjustments in Q2 2026 and significant one-time items in Q2 2025, management estimates adjusted net income of $15.2 million in Q2 2026 versus an adjusted net loss of $2.4 million in Q2 2025.
Cash, cash equivalents and investments totaled $260.2 million as of June 30, 2026, and long-term debt had been eliminated. Common shares outstanding were 59,341,906, with fully diluted shares of 69,298,10566 patients with three confirmed events, and the company plans further FDA engagement in the second half of 2026.
Zevra Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held on June 4, 2026. Stockholders elected Douglas W. Calder and Corey Watton as Class II directors to serve until the 2029 annual meeting and ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
Holders of 46,326,616 shares, or 78.37% of the 59,114,850 shares outstanding as of the record date, were represented at the meeting. Stockholders voted in favor of an amendment to declassify the board, but the proposal did not reach the required more-than 66 2/3% of outstanding shares needed for approval, so the classified board structure remains in place.
Zevra Therapeutics reported a strong turnaround in the first quarter of 2026, driven by higher product revenue and a major asset sale. Net revenue rose to $36.2 million, up 78% from Q1 2025, led by $24.6 million from MIPLYFFA and contributions from OLPRUVA, expanded access reimbursements, and AZSTARYS royalties.
The company recorded net income of $37.9 million, or $0.60 per diluted share, versus a loss a year earlier, largely reflecting a $43.3 million gain on the sale of its SDX portfolio and related proceeds of $40.5 million in the quarter. Zevra also prepaid the $63.1 million principal on its term loan, ending the period debt-free with $236.8 million in cash, cash equivalents and securities as of March 31, 2026.
Zevra Therapeutics has entered into an Asset Purchase and Settlement Agreement with Commave Therapeutics, under which Commave will buy Zevra’s SDX portfolio, including AZSTARYS® (KP415) and KP1077, for $50.0 million in cash. Commave will pay $25.0 million at signing, $20.0 million within ten business days of the effective date, and $5.0 million within three days after delivery of specified manufacturing and patent records.
The deal terminates the 2019 AZSTARYS License Agreement and settles Delaware Chancery Court litigation between the parties, with mutual releases and a dismissal with prejudice to be filed. Zevra also repaid in full approximately $63.0 million outstanding under its senior secured term loan, and states this has resulted in a strong, debt-free balance sheet and greater financial and strategic flexibility.
Zevra Therapeutics reported a strong turnaround for 2025, with net revenue of $106.5 million, up from $23.6 million in 2024, driven mainly by $87.4 million in MIPLYFFA net revenue and higher expanded‑access and royalty income.
The company generated 2025 net income of $83.2 million, or $1.40 basic EPS, compared with a prior-year net loss of $105.5 million, helped by a $148.3 million gain on sale of a priority review voucher and despite a $58.7 million intangible asset impairment.
Q4 2025 net revenue reached $34.1 million and net income was $12.2 million. Cash, cash equivalents and securities totaled $238.9 million as of December 31, 2025, supporting continued investment in MIPLYFFA, OLPRUVA and the celiprolol VEDS program.
The company highlighted progress for MIPLYFFA in Niemann‑Pick type C, including growing U.S. uptake and an EMA marketing application under review, and ongoing enrollment in the Phase 3 DiSCOVER trial for celiprolol. Zevra also relocated its headquarters to Boston and appointed Justin Renz as Chief Financial Officer, with a $520,000 base salary and options to purchase 300,000 shares vesting over four years.
Zevra Therapeutics, Inc. reported a leadership change in its finance organization. The board appointed Timothy Sangiovanni, currently Senior Vice President, Finance and Corporate Controller and principal accounting officer, to serve as interim principal financial officer effective January 1, 2026. He has held senior finance and reporting roles at the company since 2015. The company noted that there was no change to Mr. Sangiovanni’s compensation arrangements in connection with this interim appointment.
Zevra Therapeutics, Inc. reported that its Chief Financial Officer, Treasurer, and principal financial officer, R. LaDuane Clifton, has decided to resign effective December 31, 2025 to pursue other professional opportunities. The company and Mr. Clifton entered into a Separation Agreement under which he will receive separation benefits after his departure, including cash payments equal to 12 months of his annual base salary, an annual bonus equal to 40% of his base salary, up to 12 months of company-paid COBRA continuation coverage, and full vesting of his outstanding equity awards. These benefits are conditioned on his continued compliance with non-disparagement, confidentiality, non-competition, and non-solicitation covenants. Zevra has begun a search process to identify a new chief financial officer and issued a press release describing these matters.
Zevra Therapeutics (ZVRA) reported it has furnished a press release announcing financial results and corporate updates for the third quarter ended September 30, 2025. The company also scheduled a conference call and audio webcast for November 5, 2025 at 4:30 p.m. ET to discuss these updates.
The press release is furnished as Exhibit 99.1 and, as stated, is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings except as expressly specified.
Zevra Therapeutics announced it issued a press release on August 12, 2025 reporting financial results and corporate updates for the quarter ended June 30, 2025. The company scheduled a conference call and audio webcast for Tuesday, August 12, 2025 at 4:30 p.m. ET to discuss those results. The press release is furnished as Exhibit 99.1 to this Form 8-K and is explicitly furnished, not filed, so it is not incorporated by reference into Zevra's other securities filings. The Form 8-K does not include financial statements or tables within the filing itself.